Akari Therapeutics to Host Webinar on HSCT-TMA and the Potential of Nomacopan
Akari Therapeutics, Plc, a leading biotechnology company specializing in advanced therapies for autoimmune and inflammatory diseases, has announced its plans to host a virtual key opinion leader event on October 19, 2023, at 11:30 am ET. The primary focus of this event will be to discuss the patient care landscape for hematopoietic stem cell transplant-related […]
BD² Announces $18 Million in Grants to Understand Biology of Bipolar Disorder
BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder has recently declared its inaugural round of Discovery Research grants, amassing a total of $18 million. This significant financial commitment is aimed at fostering collaboration and directing concentrated funding towards understanding the biology of bipolar disorder. Key Highlights: Conclusion: BD²’s commitment to understanding bipolar disorder, especially through […]
Orchard Therapeutics Moves Closer to a Breakthrough Treatment for MLD
Orchard Therapeutics, a global leader in gene therapy, has recently made significant strides in the development of a treatment for metachromatic leukodystrophy (MLD). Here’s a detailed summary of the press release: Key Developments: Insights from Orchard Therapeutics: Bobby Gaspar, M.D., Ph.D., co-founder and CEO of Orchard Therapeutics, expressed the company’s commitment to addressing the urgent […]
BioRestorative Therapies Activates Northwell Health for Phase 2 Clinical Trial on Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc., a clinical-stage company specializing in stem cell-based therapies, has announced the activation of Northwell Health, the largest healthcare provider in New York State, for its ongoing Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). This activation permits patients in New York to participate in the BRTX-100 trial. The collaboration between […]
Neuroplast Completes Phase II Clinical Trial Inclusion for Traumatic Spinal Cord Injury
Neuroplast, a Dutch clinical-stage biotech company, has successfully concluded the patient inclusion for its Phase II clinical trial, focusing on Traumatic Spinal Cord Injury (TSCI). Here are the key details: Thought-Provoking Questions/Insights: Original Press Release
Excision BioTherapeutics’ Groundbreaking Gene Therapy for HIV: A Closer Look
Excision BioTherapeutics, a clinical-stage biotechnology company, has recently made headlines with its announcement regarding the publication of pre-clinical data supporting its innovative CRISPR-based gene therapy candidate, EBT-101. This therapy is designed to functionally cure HIV-1. Here’s a detailed summary of the press release: Key Findings: CEO’s Statement: Daniel Dornbusch, the Chief Executive Officer of Excision, […]
Unlocking Burn Healing: Aegle’s Breakthrough Therapy
Aegle Therapeutics Corp., a clinical-stage biotechnology company, has announced the initiation of its Phase 1/2a clinical trial, marking the dosing of its first patient. The trial will focus on the administration of AGLE-102™, a novel therapy designed to treat severe second-degree burns. AGLE-102™ is an investigational product made up of native extracellular vesicles, which are […]
2023’s Inventor: Dr. Laurencin’s Regenerative Breakthrough
The Intellectual Property Owners Education Foundation (IPOEF) has honored Dr. Cato T. Laurencin with the esteemed title of “Inventor of the Year” for 2023. This recognition is attributed to Dr. Laurencin’s revolutionary advancements in the field of regenerative engineering. His pioneering work has paved the way for clinical systems that facilitate the healing and regeneration […]
Caring Cross Unveils Affordable Genetic Therapy Strategies
New press release announces the role of Caring Cross, a non-profit organization, in a newly published white paper from the Innovative Genomics Institute, titled “Making Genetic Therapies Affordable and Accessible.” The white paper is the result of yearlong research and focuses on strategies to increase the affordability and accessibility of genetic therapies, including CAR-T technology […]
$32.3M Boost: City of Hope’s Groundbreaking Therapies
City of Hope, a prominent cancer research and treatment organization in the United States, has received a grant of $32.3 million from the California Institute for Regenerative Medicine (CIRM). Funding Allocation The funds will be used to support three novel Phase 1 clinical trials that focus on innovative cell and gene therapy treatments for patients […]